


We Claim:

1. A method of treating or preventing an angiogenesis-related disorder in a patient suffering from or predisposed to such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:



wherein

- R = H, C₁₋₄ (un)branched alkyl, CF₃, SR⁴;
Y = OR', NR''R';
R' = H, C₁₋₁₀ (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),
-(CH₂)_nZ(CH₂)_nA;
n = 2-6;
n' = 1-6;
Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR³, NR³C(=O), S(O)_{n²},
CHOR³, NR³;
n² = 0-2;
R³ = H, C₁₋₆ (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below);
A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH₂)_nOR³;
R'' = H, OH, OR';
X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)_{n²}R⁴, CF₃, R⁴, NO₂;

$R^4 = C_{1-6}$ (un)branched alkyl;

$m = 0-3$;

$m' = 0-5$; and

$W = O, H$.

5

2. The method of Claim 1 wherein

$R = H, C_{1-2}$ alkyl;

$Y = NR'R''$;

$R' = H, C_{1-6}$ (un)branched alkyl, $-(CH_2)_nZ(CH_2)_nA$;

10 $Z = \text{nothing}, O, CHOR^3, NR^3$;

$R_3 = H$;

$A = H, OH, (\text{un})\text{substituted aryl}$ (substitution as defined by X below);

X and X' independently = H, F, Cl, Br, CN, CF_3 , OR' , SR^4 , R^4 ;

$R'' = H$;

15 $R^4 = C_{1-4}$ (un)branched alkyl;

$m = 0-2$;

$m' = 0-2$;

$W = H$;

$n = 2-4$; and

20 $n' = 0-3$.

3. The method of Claim 2 wherein the 3-benzoylphenylacetic acid or derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide; and
25 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

4. The method of Claim 1 wherein the angiogenesis-related disorder is an ophthalmic angiogenesis-related disorder.

30 5. The method of Claim 4 wherein the 3-benzoylphenylacetic acid or derivative is topically administered to the eye.

6. The method of Claim 5 wherein the therapeutically effective amount of 3-benzoylphenylacetic acid or derivative is from about 0.001 to about 4.0% (w/v).

5 7. The method of Claim 4 wherein the angiogenesis-related disorder is selected from the group consisting of exudative macular degeneration; proliferative diabetic retinopathy; ischemic retinopathy; retinopathy of prematurity; neovascular glaucoma; iritis rubeosis; corneal neovascularization; cyclitis; sickle cell retinopathy; and pterygium.

10 8. The method of Claim 1 wherein the 3-benzoylphenylacetic acid or derivative is administered orally, intravenously, in a subconjunctival injection or implant, in a sub-Tenon's injection or implant, in an intravitreal injection or implant, or in a surgical irrigating solution.

15 9. The method of Claim 1 wherein the angiogenesis-related disorder is selected from the group consisting of prostate cancer; lung cancer; breast cancer; bladder cancer; renal cancer; colon cancer; gastric cancer; pancreatic cancer; ovarian cancer; melanoma; hepatoma; sarcoma; and lymphoma.